N-sulfonyl peptide-hybrids as a new class of dengue virus protease inhibitors

Henchal, 1999, The dengue viruses, Clin. Microbiol. Rev., 3, 379 World Health Organization Guzmán, 2002, Dengue: an update, Lancet Infect. Dis., 2, 33, 10.1016/S1473-3099(01)00171-2 Gubler, 1998, Dengue and dengue hemorrhagic fever, Clin. Microbiol. Rev., 11, 480, 10.1128/CMR.11.3.480 Kyle, 2008, Global spread and persistence of dengue, Annu. Rev. Microbiol., 62, 71, 10.1146/annurev.micro.62.081307.163005 Bhatt, 2013, The global distribution and burden of dengue, Nature, 496, 504, 10.1038/nature12060 World Health organization. Dengue guidelines for diagnosis, treatment, prevention and control: New Edition. https://www.who.int/rpc/guidelines/9789241547871/en/ (accessed Mar 31, 2020). Suthar, 2013, West Nile virus infection and immunity, Nat. Rev. Microbiol., 11, 115, 10.1038/nrmicro2950 McCauley, 2016, Hepatitis C virus NS3/4A protease inhibitors, Curr. Opin. Pharmacol., 30, 84, 10.1016/j.coph.2016.07.015 De Clercq, 2009, Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV, Int. J. Antimicrob. Agents, 33, 307, 10.1016/j.ijantimicag.2008.10.010 Nitsche, 2014, Biochemistry and medicinal chemistry of the dengue virus protease, Chem. Rev., 114, 11348, 10.1021/cr500233q Behnam, 2016, The medicinal chemistry of dengue virus, J. Med. Chem., 59, 5622, 10.1021/acs.jmedchem.5b01653 Lim, 2013, Ten years of dengue drug discovery: progress and prospects, Antivir. Res., 100, 500, 10.1016/j.antiviral.2013.09.013 Barrows, 2018, Biochemistry and molecular biology of flaviviruses, Chem. Rev., 118, 4448, 10.1021/acs.chemrev.7b00719 Nitsche, 2018, Strategies towards protease inhibitors for emerging flaviviruses, 175 Boldescu, 2017, Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond, Nat. Rev. Drug Discov., 16, 565, 10.1038/nrd.2017.33 Nitsche, 2012, Retro peptide-hybrids as selective inhibitors of the dengue virus NS2B-NS3 protease, Antivir. Res., 94, 72, 10.1016/j.antiviral.2012.02.008 Nitsche, 2013, Thiazolidinone–peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture, J. Med. Chem., 56, 8389, 10.1021/jm400828u Behnam, 2014, C-Terminal residue optimization and fragment merging: discovery of a potent peptide-hybrid inhibitor of dengue protease, ACS Med. Chem. Lett., 5, 1037, 10.1021/ml500245v Behnam, 2015, Discovery of nanomolar dengue and west nile virus protease inhibitors containing a 4-benzyloxyphenylglycine residue, J. Med. Chem., 58, 9354, 10.1021/acs.jmedchem.5b01441 Weigel, 2015, Phenylalanine and phenylglycine analogues as arginine mimetics in dengue protease inhibitors, J. Med. Chem., 58, 7719, 10.1021/acs.jmedchem.5b00612 de Bont, 1999, Increased stability of peptidesulfonamide peptidomimetics towards protease catalyzed degradation, Bioorg. Med. Chem., 7, 1043, 10.1016/S0968-0896(99)00021-8 Li, 2017, Current therapy for chronic hepatitis C: the role of direct-acting antivirals, Antivir. Res., 142, 83, 10.1016/j.antiviral.2017.02.014 Smoum, 2012, Boron containing compounds as protease inhibitors, Chem. Rev., 112, 4156, 10.1021/cr608202m Markowska, 2010, Synthesis and activity of N-sulfonylamides of tripeptides as potential urokinase inhibitors, Protein Pept. Lett., 17, 1300, 10.2174/092986610792231456 Markowska, 2013, Synthesis and biological activity of N-sulfonyltripeptides with C-terminal arginine as potential serine proteases inhibitors, Int. J. Pept. Res. Therapeut., 19, 191, 10.1007/s10989-012-9338-4 Vogler, 2004, Dianhydrohexitole-based benzamidines: an efficient synthesis of new factor Xa inhibitors, Synthesis, 8, 1211 Hinkes, 2016, Optimization of cyclic plasmin inhibitors: from benzamidines to benzylamines, J. Med. Chem., 59, 6370, 10.1021/acs.jmedchem.6b00606 Künzel, 2002, 4-Amidinobenzylamine-based inhibitors of urokinase, Bioorg. Med. Chem. Lett., 12, 645, 10.1016/S0960-894X(01)00815-0 Hammami, 2012, New 3-amidinophenylalanine-derived inhibitors of matriptase, Med. Chem. Commun, 3, 807, 10.1039/c2md20074k Meyer, 2013, Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation, Biochem. J., 452, 331, 10.1042/BJ20130101 Stürzebecher, 1997, Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine, J. Med. Chem., 40, 3091, 10.1021/jm960668h Shiryaev, 2011, Virtual ligand screening of the national cancer institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the west nile virus ns3 proteinase, Assay Drug Dev. Technol., 9, 69, 10.1089/adt.2010.0309 Timiri, 2015, Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors, Bioorg. Chem., 62, 74, 10.1016/j.bioorg.2015.07.005 Koh-Stenta, 2015, Identification of covalent active site inhibitors of dengue virus protease, Drug Des. Dev. Ther., 9, 6389, 10.2147/DDDT.S94207 Liang, 2017, Phenylglycine racemization in Fmoc-based solid-phase peptide synthesis: stereochemical stability is achieved by choice of reaction conditions, Tetrahedron Lett., 58, 2325, 10.1016/j.tetlet.2017.04.047 Elgersma, 2006, Synthesis and structural investigations of N-alkylated β-peptidosulfonamide–peptide hybrids of the amyloidogenic amylin(20–29) sequence: implications of supramolecular folding for the design of peptide-based bionanomaterials, J. Org. Biomol. Chem., 4, 3587, 10.1039/B606875H Neagoie, 2012, Piperazine amide linker for cyclative cleavage from solid support: traceless synthesis of dihydroquinoxalin-2-ones, ACS Comb. Sci., 14, 399, 10.1021/co300023b Clement, 2002, Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines, Drug Metab. Rev., 34, 565, 10.1081/DMR-120005643 Behrouz, 2021, A facile approach towards amidinophenylalanine derivatives as building blocks for the synthesis of non-natural peptides and peptidomimetics, Tetrahedron Lett., 81, 10.1016/j.tetlet.2021.153342 Brenner, 1953, Herstellung von α-Aminosäureestern durch Alkoholyse der Methylester, Helv. Chim. Acta, 36, 1109, 10.1002/hlca.19530360522 Kühl, 2020, A new class of dengue and west nile virus protease inhibitors with submicromolar activity in reporter gene DENV-2 protease and viral replication assays, J. Med. Chem., 63, 8179, 10.1021/acs.jmedchem.0c00413 Dener, 2001, Large-scale syntheses of Fmoc-protected nonproteogenic amino acids: useful building blocks for combinatorial libraries, Org. Process Res. Dev., 5, 445, 10.1021/op010204f Brandstetter, 1992, Refined 2.3Å X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA: a starting point for improving antithrombotics, J. Mol. Biol., 226, 1085, 10.1016/0022-2836(92)91054-S Cheng, 1973, Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol., 22, 3099, 10.1016/0006-2952(73)90196-2 Newton, 2008, A Novel method for determination of the affinity of protein: protein interactions in homogeneous assays, J. Biomol. Screen, 13, 674, 10.1177/1087057108321086 Biron, 2005, Convenient synthesis of N-methyl amino acids compatible with Fmoc solid-phase peptide synthesis, J. Org. Chem., 70, 5183, 10.1021/jo050477z Miller, 1997, Site-selective N-methylation of peptides on solid support, J. Am. Chem. Soc., 119, 2301, 10.1021/ja9635443 Trott, 2010, Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem., 31, 455, 10.1002/jcc.21334 Noble, 2012, Ligand-bound structures of the dengue virus protease reveal the active conformation, J. Virol., 86, 438, 10.1128/JVI.06225-11 Pettersen, 2004, UCSF Chimera‒a visualization system for exploratory research and analysis, J. Comput. Chem., 25, 1605, 10.1002/jcc.20084 Yan, 2003, Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases, Eur. J. Drug Metab. Pharmacokinet., 28, 223, 10.1007/BF03190489 Jakob, 2019, Backbone modifications in peptidic inhibitors of flaviviral proteases, Bioorg. Med. Chem. Lett., 29, 1913, 10.1016/j.bmcl.2019.05.054 Amblard, 2006, Methods and protocols of modern solid phase peptide synthesis, Mol. Biotechnol., 33, 239, 10.1385/MB:33:3:239 Morris, 2009, Automated docking with selective receptor flexibility, J. Comput. Chem., 30, 2785, 10.1002/jcc.21256